Moleculin Biotech announced that the European Medicines Agency has granted Orphan Drug Designation to Annamycin for the treatment of AML.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Reveals Promising Annamycin Cancer Drug Data
- Moleculin Biotech announces preclinical data regarding anthracycline
- Moleculin Biotech Secures New Patent for Annamycin Preparation
- Moleculin Biotech announces notification from USPTO regarding Annamycin
- Moleculin Biotech price target lowered to $20 from $45 at Maxim
